{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:45:38Z","timestamp":1776192338898,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>How does a physician decide to use a recently FDA-approved life-saving device in a desperately ill child in which little prior clinical experience is available? This report presents a pediatric patient with neutropenic septic shock and multiorgan failure (MOF) with a 95% chance of death and the availability of a therapeutic device with a completely new approach to treat sepsis. This device, called the selective cytopheretic device (SCD), is a first-in-class autologous immune cell directed therapy. The SCD, when integrated into an extracorporeal blood circuit, has been shown to bind activated neutrophils and monocytes. With a simple pharmacologic maneuver within the device, the bound cells in real time are immunomodulated from a highly pro-inflammatory state to a less inflammatory phenotype. These transformed cells are then released back into the systemic circulation thereby tempering the systemic hyperinflammatory disorder. Since this cell directed therapy focuses on neutrophils, the processing of these cells in a neutropenic state may be a substantive risk resulting in further immunosuppression. On the other hand, the immunomodulation of the circulating neutrophils and monocytes, although sparse, may be beneficial to disrupt the dysregulated inflammatory state responsible for ongoing tissue damage and organ dysfunction. Prior clinical SCD trials excluded patients with neutropenia so that no prior clinical experience was available to make a difficult decision. This report presents the way the medical team approached these issues and made a therapeutic plan that resulted in a positive clinical outcome for the patient.<\/jats:p>","DOI":"10.1007\/s00467-025-06798-y","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T09:37:31Z","timestamp":1750498651000},"page":"3577-3583","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Management dilemma in choosing evolving treatments in neutropenic septic shock"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4309-1614","authenticated-orcid":false,"given":"H. David","family":"Humes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kera","family":"Luckritz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Gorga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katie","family":"Plomaritas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Hoatlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Humes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lenar","family":"Yessayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"6798_CR1","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00277-019-03622-0","volume":"98","author":"M Kochanek","year":"2019","unstructured":"Kochanek M, Schalk E, von Bergwelt-Baildon M et al (2019) Management of sepsis in neutropenic cancer patients: 2018 guidelines from the Infectious Diseases Working Party (AGIHO) and Intensive Care Working Party (iCHOP) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 98:1051\u20131069","journal-title":"Ann Hematol"},{"key":"6798_CR2","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1097\/PCC.0000000000002198","volume":"21","author":"SL Weiss","year":"2020","unstructured":"Weiss SL, Peters MJ, Alhazzani W et al (2020) Surviving sepsis campaign international guidelines for the management of septic shock and sepsis-associated organ dysfunction in children. Pediatr Crit Care Med 21:e52\u2013e106","journal-title":"Pediatr Crit Care Med"},{"key":"6798_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","volume":"44","author":"B Shakoory","year":"2016","unstructured":"Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM (2016) Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial. Crit Care Med 44:275\u2013281","journal-title":"Crit Care Med"},{"key":"6798_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1681\/ASN.0000000569","volume":"36","author":"CJ Pino","year":"2025","unstructured":"Pino CJ, Johnston KA, Westover AJ, Humes HD (2025) Selective Cytopheretic Device (QUELimmune): a leukocyte processing, immunomodulatory device. J Am Soc Nephrol 36:144\u2013146","journal-title":"J Am Soc Nephrol"},{"key":"6798_CR5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1177\/08850666231170775","volume":"38","author":"OPE Lee","year":"2023","unstructured":"Lee OPE, Kanesan N, Leow EH, Sultana R, Chor YK, Gan CS, Lee JH (2023) Survival benefits of therapeutic plasma exchange in severe sepsis and septic shock: a systematic review and meta-analysis. J Intensive Care Med 38:598\u2013611","journal-title":"J Intensive Care Med"},{"key":"6798_CR6","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.57657","volume":"8","author":"G Bottari","year":"2025","unstructured":"Bottari G, Buccione E, Bayrakci B et al (2025) Extracorporeal blood purification in european pediatric intensive care units: a consensus statement. JAMA Netw Open 8:e2457657","journal-title":"JAMA Netw Open"},{"key":"6798_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0140-6736(06)69005-3","volume":"368","author":"KA Brown","year":"2006","unstructured":"Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF (2006) Neutrophils in development of multiple organ failure in sepsis. Lancet 368:157\u2013169","journal-title":"Lancet"},{"key":"6798_CR8","doi-asserted-by":"crossref","unstructured":"Szamosfalvi B, Puri V, Sohaney R et al (2021) Regional citrate anticoagulation protocol for patients with presumed absent citrate metabolism. Kidney360 2:192\u2013204","DOI":"10.34067\/KID.0005342020"},{"key":"6798_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12882-021-02443-6","volume":"22","author":"L Yessayan","year":"2021","unstructured":"Yessayan L, Sohaney R, Puri V et al (2021) Regional citrate anticoagulation \u201cnon-shock\u201d protocol with pre-calculated flow settings for patients with at least 6 L\/hour liver citrate clearance. BMC Nephrol 22:244","journal-title":"BMC Nephrol"},{"key":"6798_CR10","doi-asserted-by":"publisher","first-page":"12747","DOI":"10.1038\/s41598-024-63121-9","volume":"14","author":"AJ Westover","year":"2024","unstructured":"Westover AJ, Humes HD, Pino CJ (2024) Immunomodulatory effects of a cell processing device to ameliorate dysregulated hyperinflammatory disease states. Sci Rep 14:12747","journal-title":"Sci Rep"},{"key":"6798_CR11","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/0022-1759(94)90048-5","volume":"171","author":"A Finn","year":"1994","unstructured":"Finn A, Rebuck N (1994) Measurement of adhesion molecule expression on neutrophils and fixation. J Immunol Methods 171:267\u2013270","journal-title":"J Immunol Methods"},{"key":"6798_CR12","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0022-1759(92)90231-H","volume":"146","author":"A Hamblin","year":"1992","unstructured":"Hamblin A, Taylor M, Bernhagen J, Shakoor Z, Mayall S, Noble G, McCarthy D (1992) A method of preparing blood leucocytes for flow cytometry which prevents upregulation of leucocyte integrins. J Immunol Methods 146:219\u2013228","journal-title":"J Immunol Methods"},{"key":"6798_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/j.1365-2567.2004.01766.x","volume":"111","author":"K Ayub","year":"2004","unstructured":"Ayub K, Hallett MB (2004) Ca2+ influx shutdown during neutrophil apoptosis: importance and possible mechanism. Immunology 111:8\u201312","journal-title":"Immunology"},{"key":"6798_CR14","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1172\/JCI116587","volume":"92","author":"MK Whyte","year":"1993","unstructured":"Whyte MK, Hardwick SJ, Meagher LC, Savill JS, Haslett C (1993) Transient elevations of cytosolic free calcium retard subsequent apoptosis in neutrophils in vitro. J Clin Invest 92:446\u2013455","journal-title":"J Clin Invest"},{"key":"6798_CR15","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S1074-7613(03)00263-2","volume":"19","author":"C Martin","year":"2003","unstructured":"Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM (2003) Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 19:583\u2013593","journal-title":"Immunity"},{"key":"6798_CR16","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000284367","volume":"2","author":"S Fox","year":"2010","unstructured":"Fox S, Leitch AE, Duffin R, Haslett C, Rossi AG (2010) Neutrophil apoptosis: relevance to the innate immune response and inflammatory disease. J Innate Immun 2:216\u2013227","journal-title":"J Innate Immun"},{"key":"6798_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1175202","volume":"325","author":"FK Swirski","year":"2009","unstructured":"Swirski FK, Nahrendorf M, Etzrodt M et al (2009) Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 325:612\u2013616","journal-title":"Science"},{"key":"6798_CR18","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1097\/MAT.0000000000000400","volume":"62","author":"B Szamosfalvi","year":"2016","unstructured":"Szamosfalvi B, Westover A, Buffington D, Yevzlin A, Humes HD (2016) Immunomodulatory device promotes a shift of circulating monocytes to a less inflammatory phenotype in chronic hemodialysis patients. ASAIO J 62:623\u2013630","journal-title":"ASAIO J"},{"key":"6798_CR19","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ekir.2017.12.012","volume":"3","author":"CJ Pino","year":"2018","unstructured":"Pino CJ, Westover AJ, Johnston KA, Buffington DA, Humes HD (2018) Regenerative medicine and immunomodulatory therapy: insights from the kidney, heart, brain, and lung. Kidney Int Rep 3:771\u2013783","journal-title":"Kidney Int Rep"},{"key":"6798_CR20","volume":"5","author":"HD Humes","year":"2023","unstructured":"Humes HD, Goldstein SL, Yessayan LT, Catanzaro DA, Scribe EC, Iyer SPN, Chung KK (2023) Safety summary of the selective cytopheretic device: a review of safety data across multiple clinical trials in ICU patients with acute kidney injury and multiple organ failure. Crit Care Explor 5:e0995","journal-title":"Crit Care Explor"},{"key":"6798_CR21","doi-asserted-by":"publisher","first-page":"2459349","DOI":"10.1080\/0886022X.2025.2459349","volume":"47","author":"L Yessayan","year":"2025","unstructured":"Yessayan L, Pino CJ, Humes HD (2025) Extracorporeal therapies in sepsis: a comprehensive review of the selective cytopheretic device, polymyxin B and seraph cartridges. Ren Fail 47:2459349","journal-title":"Ren Fail"},{"key":"6798_CR22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0273138","volume":"18","author":"HD Humes","year":"2023","unstructured":"Humes HD, Aaronson KD, Buffington DA, Sabbah HN, Westover AJ, Yessayan LT, Szamosfalvi B, Pagani FD (2023) Translation of immunomodulatory therapy to treat chronic heart failure: preclinical studies to first in human. PLoS One 18:e0273138","journal-title":"PLoS ONE"},{"key":"6798_CR23","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-022-05692-1","volume":"38","author":"SL Goldstein","year":"2023","unstructured":"Goldstein SL, Yessayan LT, Krallman KA, Collins M, Benoit S, Westover A, Humes HD (2023) Use of extracorporeal immunomodulation in a toddler with hemophagocytic lymphohistiocytosis and multisystem organ failure. Pediatr Nephrol 38:927\u2013931","journal-title":"Pediatr Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06798-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06798-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:02:33Z","timestamp":1759276953000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06798-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":23,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["6798"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06798-y","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"5 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from the parents for emergency use of SCD and signed informed consent regarding publishing this case report and clinical data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"H. David Humes and Michael Humes have financial interest in SeaStar Medical, Inc. and Innovative Biotherapies, Inc. All other authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}